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Method of Mutation Analysis May Contribute to
Discrepancies in Reports of V599EBRAF Mutation
Frequencies in Melanocytic Neoplasms
To the Editor:
Since the initial discovery that BRAF mutations occur in
460% of primary melanomas (Davies et al, 2002), multiple
studies have reported widely discrepant BRAF mutation
frequencies in melanocytic neoplasms of all stages of pro-
gression (Dong et al, 2003; Gorden et al, 2003; Kumar et al,
2003; Lang et al, 2003; Maldonado et al, 2003; Pollock et al,
2003; Uribe et al, 2003; Yazdi et al, 2003; Kumar et al, 2004;
Tsao et al, 2004). Resolving these discrepancies has critical
implications for clarifying the role of BRAF mutations in
melanocytic tumorigenesis and for determining the rele-
vance of BRAF as a potential target for therapy. We noted
that the lowest frequencies of BRAF mutation were reported
in studies that used direct fluorescent sequencing as the
sole method of mutational analysis (Dong et al, 2003; Gor-
den et al, 2003; Lang et al, 2003; Yazdi et al, 2003). This
finding prompted us to compare the sensitivities of bidirec-
tional direct fluorescent sequencing and allele-specific po-
lymerase chain reaction (AS-PCR) to detect the V599EBRAF
mutation and to evaluate whether method of mutation anal-
ysis could be one factor contributing to variations in mu-
tation frequencies.
Initially, titration assays were performed, demonstrating
that AS-PCR detects the V599EBRAF mutation with greater
sensitivity compared to direct fluorescent sequencing.
Figure 1
Results of titration assay assessing the sensitivity of direct fluo-
rescent sequencing versus allele-specific polymerase chain reac-
tion (AS-PCR) to detect the V599EBRAF mutation. (a) Results of
titration assay assessing the sensitivity of direct fluorescent sequencing
to detect the V599EBRAF mutation. DNA sequencing profiles showing
the results of direct fluorescent sequencing of template DNA containing
decreasing percentages of mutant V599EBRAF. The 100% wild-type
BRAF (T) sequence contained template DNA that was obtained from
normal human fibroblast cells in which only the wild-type BRAF gene
was present. The 100% mutant V599EBRAF (A) sequence contained
template DNA that was obtained from the melanoma cell line UACC
903 in which 100% of the cells were mutant. The remaining sequencing
profiles represent varying concentrations of template genomic DNA
from the melanoma cell line UACC 903 diluted with DNA from normal
human diploid fibroblasts to give the indicated concentration of wild-
type to mutant V599EBRAF. Asterisk indicates the minimum concentra-
tion at which mutant V599EBRAF DNA must be present to be able to
discern the presence of a mutant spike from background. (b) Results of
titration assay assessing the sensitivity of AS-PCR to detect the
V599EBRAF mutation. Ethidium bromide-stained gel showing the results
of the AS-PCR analysis of template DNA containing decreasing per-
centages of mutant V599EBRAF. Lanes 1 and 2 serve as negative con-
trols since template DNA contained only the wild-type BRAF gene from
human lymphoblast and fibroblast cells, respectively. Lane 3 represents
results from template DNA obtained from the melanoma cell line UACC
903 in which 100% of the cells contain mutant V599EBRAF. Lanes 4–10
contain template genomic DNA from the melanoma cell line UACC 903
diluted with DNA from normal human diploid fibroblasts to give the
indicated concentration of wild-type to mutant V599EBRAF. Lane 11 is a
water only negative control. Asterisk indicates the minimum concen-
tration at which mutant V599EBRAF DNAmust be present to be detected
by AS-PCR. The GAPDH control bands lack uniform intensity due to
preferential PCR amplification in multiplex reactions, but does not im-
pact the interpretation of our results (Markoulatos et al, 2002).
Abbreviation: AS-PCR, allele-specific polymerase chain reaction
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UACC 903 genomic DNA, a melanoma cell line containing
the V599EBRAF mutation, was mixed with increasing
amounts of normal human diploid fibroblast genomic
DNA. Direct fluorescent sequencing and AS-PCR were per-
formed at each stage of the dilution. Direct fluorescent se-
quencing required  5% of mutant DNA in the total mixture
in order to detect the V599EBRAF mutation. (Fig 1a). Below
the 5% threshold, the presence of a mutant spike could not
reliably be discerned from background on the electrophe-
rogram and was determined to be wild-type. By compar-
ison, AS-PCR reliably detected the V599EBRAF mutant DNA
if it comprised 1% or more of the mixture of mutant and
wild-type DNA. At a 1% concentration of V599EBRAF mutant
DNA, a mutant band was clearly visible on the gel of the AS-
PCR products (Fig 1b).
Next, both direct fluorescent sequencing and AS-PCR
were performed to screen for the V599EBRAF mutation on
DNA extracted from macrodissected human tissue samples
obtained from conventional paraffin-embedded blocks ar-
chived at the Penn State Milton S. Hershey Medical Center.
The institutional review board of the Penn State College of
Medicine/Penn State Milton S. Hershey Medical Center ap-
proved the study, which was conducted according to the
Declaration of Helsinki Principles. Conditions for direct flu-
orescent sequencing and AS-PCR have been previously
described (Davies et al, 2002; Pollock et al, 2003). Both
methods of mutation analysis were successful in 67 sam-
ples, including nine atypical nevi, 34 primary melanomas,
and 24 metastatic melanomas. PCR amplification of exon
15 of the BRAF gene followed by direct fluorescent se-
quencing detected the V599EBRAF mutation in 22% (two of
nine) of atypical nevi, 50% (17 of 34) primary melanomas,
and 71% (17 of 24) metastatic melanomas. By comparison,
AS-PCR detected the mutation in seven additional samples,
including 44% (four of nine) of atypical nevi, 59% (20 of 34)
of primary melanomas, and 79% (19 of 24) of metastatic
melanomas (Table I). Consistent with the results of the tit-
ration assay, AS-PCR detected the mutation with higher
frequency than direct fluorescent sequencing in each of
the three subgroups (atypical nevi, p¼ 0.16; primary me-
lanomas, p¼0.083; and metastatic melanomas, p¼0.16
[McNemar’s test for each group]). The overall mutation fre-
quency was significantly higher using AS-PCR (64% [43 of
67]) compared to direct sequencing (54% [36 of 67])
(p¼ 0.0082, McNemar’s test). To ensure that mutations de-
tected by AS-PCR did not represent false positives, normal
DNA derived from human diploid fibroblasts and lympho-
blasts was used as negative controls (Fig 2). As a further
measure to preclude contamination, genomic DNA was
isolated from additional sections from the tissue blocks of
three of seven samples in which the mutation was detected
by AS-PCR but not by direct fluorescent sequencing. In all
three samples, the presence of the mutation was repro-
duced on subsequent AS-PCR. The mutant band was then
cut from the AS-PCR gel, and direct fluorescent sequencing
of the isolated DNA confirmed the mutant sequence in each
of the three samples. In our study, therefore, both titration
assays and direct comparison of mutation analysis of
human tissues demonstrated that AS-PCR detects the
V599EBRAF mutation with greater sensitivity than direct flu-
orescent sequencing. Similar to our results, another study
which used both AS-PCR and direct sequencing for detec-
tion of V599EBRAF mutations had samples in which AS-PCR,
but not direct sequencing, detected the mutant allele (Pol-
lock et al, 2003). Since we analyzed only two methods of
mutation analysis, we cannot comment on the sensitivities
of other methods of mutation analysis, such as PCR-single-
strand conformation polymorphism/heteroduplex analysis,
Figure2
Results of allele-specific polymerase chain reaction (AS-PCR)
analysis and direct fluorescent sequencing for the V599EBRAF mu-
tation in human tissue. (a) Ethidium bromide-stained AS-PCR gel
showing the absence of the V599EBRAF mutant band in the first three
control lanes representing water, fibroblast genomic DNA and lympho-
blast genomic DNA, respectively. A mutant band is clearly visible in lane
4, representing the positive control SK-Mel-111 cell line known to con-
tain the V599EBRAF mutation. Lanes 5, 6, and –7 show a clear mutant
band from tumor samples in which direct fluorescent sequencing also
detected a mutant allele with high, medium, and low levels of intensity,
respectively. The final column, representing tumor #18, shows a clear
mutant band that was undetectable by direct fluorescent sequencing.
(b) Direct fluorescent sequencing of DNA from tumor #18, which shows
a wild-type sequence despite detection of the mutation by AS-PCR.
Table I. Comparison of frequencies of V599EBRAF mutation by
direct ﬂuorescent sequencing and AS-PCR
Melanocytic lesion Direct sequencing AS-PCR
Atypical nevi 22% (2/9) 44% (4/9)
Primary melanomas 50% (17/34) 59% (20/34)
Metastatic melanomas 71% (17/24) 79% (19/24)
Combined frequency 54% (36/67) 64% (43/67)
p¼ 0.0082, McNemar’s test comparing detection rates of direct flu-
orescent sequencing and AS-PCR.
AS-PCR, allele-specific polymerase chain reaction.
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which has been used by some authors to assess BRAF
mutation frequencies (Kumar et al, 2003, 2004; Tsao et al,
2004). Nevertheless, our findings indicate that differences in
the sensitivities of methods of mutation analysis may be one
factor contributing to discrepancies in reports of mutation
frequency. Other factors may also contribute to discrepan-
cies in mutation frequency, such as selection of melanomas
from skin with intermittent sun exposure versus from chron-
ically sun-damaged and relatively unexposed skin (Maldon-
ado et al, 2003).
Resolving discrepancies in reported mutation frequen-
cies will help to clarify current conflicts about the role of
BRAF mutations in melanocytic tumor progression. Due
to detection of high rates of BRAF mutation in subsets of
benign and atypical nevi, most authors conclude that mu-
tation of BRAF is a critical step in the initiation of many
melanocytic neoplasms (Pollock et al, 2003; Uribe et al,
2003; Yazdi et al, 2003; Kumar et al, 2004). Moreover, most
authors agree that BRAF mutation alone appears insuffi-
cient to cause a melanoma (Pollock et al, 2003; Uribe et al,
2003; Yazdi et al, 2003), as evidenced by the fact that the
majority of nevi do not progress to melanoma (Bevona et al,
2003). By contrast, Dong et al (2003) conclude that BRAF
mutations are not involved in the initiation of the great ma-
jority of melanomas, but instead reflect a progression event
in melanoma tumorigenesis. This conflicting conclusion is
based on their finding that BRAF mutation was present in
only 10% of radial growth phase compared to 63% of ver-
tical growth phase and 62% of metastatic melanomas
[pooled statistical difference, po0.01] (Dong et al, 2003).
Our results suggest that the low rate of mutation detected in
radial growth phase melanomas may have resulted in part
from the lack of sensitivity of direct sequencing, which was
the sole method of mutational analysis used in the study by
Dong et al.
Resolving discrepancies in BRAF mutation frequencies
also has important therapeutic implications. Increasing
evidence suggests that suppression of BRAF and the
MAP kinase pathway may be a therapeutic option against
melanomas with BRAF mutation (Sebolt-Leopold, 2000;
Collisson et al, 2003; Hingorani et al, 2003; Tuveson et al,
2003; Sharkey et al, 2004). Whereas several studies, in-
cluding our own, report a BRAF mutation rate of 460% in
metastatic melanomas (Dong et al, 2003; Kumar et al, 2003;
Pollock et al, 2003), others studies, which used direct flu-
orescent sequencing as the sole method of mutation
analysis, report mutation rates as low as 21%–40% in
metastatic melanomas (Gorden et al, 2003; Lang et al, 2003;
Yazdi et al, 2003). These low rates of mutation suggest that
the development of therapies that inhibit BRAF activity may
be relevant to fewer melanomas than initially suspected.
In conclusion, using both titration assays and mutation
analysis in human tissue samples, our study demonstrates
that AS-PCR detects the V599EBRAF mutation with greater
sensitivity than direct fluorescent sequencing. Our results
suggest that method of mutation analysis may be one factor
contributing to widely discrepant reports of BRAF mutation
frequency. Accurate methods of mutation analysis are
necessary to clarify the role of BRAF mutation in melanocy-
tic tumorigenesis and to determine the percentage of
melanomas for which BRAF inhibitors will be relevant.
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